Literature DB >> 21358709

Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.

O Howes, S Bose, F Turkheimer, I Valli, A Egerton, D Stahl, L Valmaggia, P Allen, R Murray, P McGuire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21358709      PMCID： PMC3662873          DOI： 10.1038/mp.2011.20

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  12 in total

Review 1.  The role of dopamine for the pathophysiology of schizophrenia.

Authors:  E M Meisenzahl; G J Schmitt; J Scheuerecker; H-J Möller
Journal:  Int Rev Psychiatry       Date:  2007-08

2.  Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States.

Authors:  Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby
Journal:  Aust N Z J Psychiatry       Date:  2005 Nov-Dec       Impact factor: 5.744

3.  Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.

Authors:  Thomas H McGlashan; Robert B Zipursky; Diana Perkins; Jean Addington; Tandy Miller; Scott W Woods; Keith A Hawkins; Ralph E Hoffman; Adrian Preda; Irvin Epstein; Donald Addington; Stacy Lindborg; Quynh Trzaskoma; Mauricio Tohen; Alan Breier
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

Review 4.  Increased dopamine transmission in schizophrenia: relationship to illness phases.

Authors:  M Laruelle; A Abi-Dargham; R Gil; L Kegeles; R Innis
Journal:  Biol Psychiatry       Date:  1999-07-01       Impact factor: 13.382

Review 5.  Molecular brain imaging and the neurobiology and genetics of schizophrenia.

Authors:  A Heinz; B Romero; J Gallinat; G Juckel; D R Weinberger
Journal:  Pharmacopsychiatry       Date:  2003-11       Impact factor: 5.788

6.  Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

Authors:  Oliver D Howes; Andrew J Montgomery; Marie-Claude Asselin; Robin M Murray; Isabel Valli; Paul Tabraham; Elvira Bramon-Bosch; Lucia Valmaggia; Louise Johns; Matthew Broome; Philip K McGuire; Paul M Grasby
Journal:  Arch Gen Psychiatry       Date:  2009-01

7.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson
Journal:  Arch Gen Psychiatry       Date:  2002-10

8.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America.

Authors:  Tyrone D Cannon; Kristin Cadenhead; Barbara Cornblatt; Scott W Woods; Jean Addington; Elaine Walker; Larry J Seidman; Diana Perkins; Ming Tsuang; Thomas McGlashan; Robert Heinssen
Journal:  Arch Gen Psychiatry       Date:  2008-01

9.  Presynaptic regulation of dopamine transmission in schizophrenia.

Authors:  Gholson J Lyon; Anissa Abi-Dargham; Holly Moore; Jeffrey A Lieberman; Jonathan A Javitch; David Sulzer
Journal:  Schizophr Bull       Date:  2009-06-12       Impact factor: 9.306

Review 10.  Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.

Authors:  Oliver D Howes; Andrew J Montgomery; Marie-Claude Asselin; Robin M Murray; Paul M Grasby; Philip K McGuire
Journal:  Br J Psychiatry Suppl       Date:  2007-12
View more
  116 in total

1.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Authors:  Oliver D Howes; Paul Shotbolt; Michael Bloomfield; Kirstin Daalman; Arsime Demjaha; Kelly M J Diederen; Kemal Ibrahim; Euitae Kim; Philip McGuire; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency.

Authors:  Corina O Bondi; Ameer Y Taha; Jody L Tock; Nelson K B Totah; Yewon Cheon; Gonzalo E Torres; Stanley I Rapoport; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

4.  The neuromodulator of exploration: A unifying theory of the role of dopamine in personality.

Authors:  Colin G Deyoung
Journal:  Front Hum Neurosci       Date:  2013-11-14       Impact factor: 3.169

Review 5.  Antipsychotic interventions in prodromal psychosis: safety issues.

Authors:  Chen-Chung Liu; Arsime Demjaha
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 6.  Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome.

Authors:  Scott Richard Clark; Klaus Oliver Schubert; Bernhard Theodor Baune
Journal:  J Neural Transm (Vienna)       Date:  2014-10-16       Impact factor: 3.575

7.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

8.  Developmental timing and critical windows for the treatment of psychiatric disorders.

Authors:  Oscar Marín
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

9.  The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2020-07-14       Impact factor: 7.853

Review 10.  An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Biol Psychiatry       Date:  2016-06-01       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.